affron®, the New Saffron Extract from Pharmactive that Improves Mood in Adolescents

Share

The company Pharmactive, a pioneer in proven effective phytotherapy, conducts significant research on medicinal plants native to the Mediterranean from the RD laboratories of the Madrid Scientific Park Foundation.

One of its lines of work focuses on saffron raw material, for which Pharmactive has identified and extracted only its bioactive principles with therapeutic efficacy to improve people’s mood. Statistics show that more and more people are turning to natural products for the treatment of stress or anxiety, symptoms associated, for example, with depression, which is considered one of the most diagnosed pathologies today, which is why Pharmactive begins to use this ingredient as the basis of its work.

Pharmactive R Team

affron®, a patented saffron extract, both in its formula and therapeutic application, with genetic certification (100% Crocus sativus L.) and 100% stable (3 years).

affron® is presented as the first commercial saffron extract analyzed by High-Performance Liquid Chromatography (HPLC), an objective, reproducible, and reliable analysis method.

Due to its standardization, extraction process, traceability (from cultivation to final ingredient), and concentration, this ingredient is quite different from saffron for everyday use.

Five clinical studies make this ingredient the saffron extract with the greatest scientific support on the market and endorse its effectiveness and safety, with no reported side effects or toxicity. The latest of these confirms its efficacy in adolescents.

CEO and R Director of PharmactiveA 100% Natural Product Indicated for the Treatment of Anxiety and Depression Symptoms, Now Also for Adolescents

The Journal of Affective Disorders has recently published the first study conducted in Australia on adolescents with symptoms of depression, involving 80 young people aged 12 to 16, and it has been conclusive, showing that affron® significantly improves symptoms associated with depression (such as sadness or anxiety) compared to the placebo group.

Two mechanisms of action stand out for achieving these improvements. On one hand, affron® has a great antioxidant capacity, thus preventing oxidative damage that occurs during long periods of stress and anxiety. On the other hand, it is also a potent inhibitor of neurotransmitter reuptake, increasing the concentrations of serotonin, dopamine, and norepinephrine, all related to mood.

Related news

SPEAKERS

Space, defense, and semiconductors

Foto de Francisco Marín de CITT Tecnologías del Espacio
Francisco Marín, Director CITT Space Technologies
Daniel Granados, Director CITT Semiconductors
Foto de David Gómez de Tekniker
David Gómez, Director of Advanced Manufacturing Technologies Tekniker
Luis Benaite, Director of Electronic Warfare Laboratory Funditec
Paloma Domingo, Deputy Director CSIC Foundation
José Antonio González, Co-founder YPlasma
Foto de Daniel González, CEO de Nanostine
Daniel González, CEO Nanostine
Nicolai Lavroff, Business Development G2 Zero

Smart health

Foto de Micaela Martelli

Micaela Martelli, Director of Sectorial Solutions Telefónica

Foto de Ana Isabel González de la Com. de Madrid
Ana Isabel González, Head of Health Research Area Community of Madrid
Foto de Rosa Lillo
Rosa Lillo, Director IBiDat – Big Data Institute UC3M
Foto de Ángel Sánchez, de Quirónsalud
Ángel Sánchez, Medical Director Quirónsalud
Foto de Marta Pedrosa, de Cinfa
Marta Pedrosa, Innovation Department Cinfa
Foto de Felip Miralles de Eurecat
Felip Miralles, Director of Health Technologies Eurecat
Clément Destoumieux, Spanish Startups Association
Jesús Prada, CEO Horus ML
Raúl Alelú, CEO Healthy Minds
Foto de Blanca Caballero, de Nanological

Blanca Caballero, CEO Nanological

Carolina Gago, COO IOT Lenses

Energy vectors and circularity

María Cano, Node Director Greentech Retech
Foto de Pedro Pereira, fundador de Nanostech
Pedro Pereira, CTO NanosTech and Professor Emeritus
Foto de Jesús Montes de Moeve
Jesús Montes, Energy Technology Intelligence Moeve
Foto de Lidia Caramazana de Naturgy
Lidia Caramazana, Innovation Manager Naturgy
Miquel Rovira, Director of Sustainability Eurecat
Foto de Roberto Clemente, CEO de Gnanomat
Roberto Clemente, CEO Gnanomat
Foto de Rafael Mombiedro, CEO de Empirical Advances
Rafael Mombiedro, CEO Empirical Advances

María Urbano, CEO EvoEnzyme

Institutions

Foto de Marina Villegas de la Com. de Madrid
Marina Villegas, General Director of Research and Technological Innovation Community of Madrid
Foto de Óscar Romera del Ayto. Madrid
Óscar Romera, General Coordinator of Economy, Trade and Consumer Affairs Madrid City Council
Foto de Marta del Castillo Vázquez, Dir.ª Gral. Parque Científico de Madrid
Marta del Castillo, General Director Madrid Science Park
Félix Zamora, Vice-Rector for Transfer, Innovation and Culture UAM
Foto de María Inmaculada López, directora de Compluemprende

Mª Inmaculada López, Director Compluemprende

Javier Etxabe, Head of Entrepreneurship and Innovation Area, Vice President for Innovation and Transfer CSIC
Carlos Herranz, Coordinator of the Secretariat of State for Digitalization and AI Ministry of Digital Transformation
Foto de Andrés Ubierna de CDTI
Andrés Ubierna, Head of Capitalization and Technology Transfer Division CDTI
Ignacio Liñán, Communications and Promotion Department Enisa
Foto de Juan Rodríguez de ClarkeModet (Arosa I+D)
Juan Rodríguez, Innovation Sales Director ClarkeModet (Arosa I+D)

Eduardo Díaz, Director of EBT Office Fund. Madri+d